Why Don’t the Mutant Cells That Evade DNA Repair Cause Cancer More Frequently? Importance of the Innate Immune System in the Tumor Microenvironment
Open Access
- 6 March 2023
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (5) , 5026
Abstract
The standard of care for most malignant solid tumors still involves tumor resection followed by chemo- and radiation therapy, hoping to eliminate the residual tumor cells. This strategy has been successful in extending the life of many cancer patients. Still, for primary glioblastoma (GBM), it has not controlled recurrence or increased the life expectancies of patients. Amid such disappointment, attempts to design therapies using the cells in the tumor microenvironment (TME) have gained ground. Such “immunotherapies” have so far overwhelmingly used genetic modifications of Tc cells (Car-T cell therapy) or blocking of proteins (PD-1 or PD-L1) that inhibit Tc-cell-mediated cancer cell elimination. Despite such advances, GBM has remained a “Kiss of Death” for most patients. Although the use of innate immune cells, such as the microglia, macrophages, and natural killer (NK) cells, has been considered in designing therapies for cancers, such attempts have not reached the clinic yet. We have reported a series of preclinical studies highlighting strategies to “re-educate” GBM-associated microglia and macrophages (TAMs) so that they assume a tumoricidal status. Such cells then secrete chemokines to recruit activated, GBM-eliminating NK cells and cause the rescue of 50–60% GBM mice in a syngeneic model of GBM. This review discusses a more fundamental question that most biochemists harbor: “since we are generating mutant cells in our body all the time, why don’t we get cancer more often?” The review visits publications addressing this question and discusses some published strategies for re-educating the TAMs to take on the “sentry” role they initially maintained in the absence of cancer.Keywords
Funding Information
- National Cancer Institute (CA253069, PSC-CUNY 52, R01GM123508, TRADB-49-271)
- CUNY University Committee on Research Awards (CA253069, PSC-CUNY 52, R01GM123508, TRADB-49-271)
- National Institutes of Health (CA253069, PSC-CUNY 52, R01GM123508, TRADB-49-271)
- Professional Staff Congress-City University of New York (CA253069, PSC-CUNY 52, R01GM123508, TRADB-49-271)
This publication has 103 references indexed in Scilit:
- Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2‐induced STAT3 activationEMBO Molecular Medicine, 2013
- Targeting the Shift from M1 to M2 Macrophages in Experimental Autoimmune Encephalomyelitis Mice Treated with FasudilPLOS ONE, 2013
- Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and ImmunityImmunity, 2011
- Microtubule-Targeted Chemotherapeutic Agents Inhibit Signal Transducer and Activator of Transcription 3 (STAT3) SignalingMolecular Pharmacology, 2010
- Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancerBritish Journal of Cancer, 2008
- Optimal amount of monocyte chemoattractant protein‐1 enhances antitumor effects of suicide gene therapy against hepatocellular carcinoma by M1 macrophage activationCancer Science, 2008
- Epidemiology and etiology of gliomasActa Neuropathologica, 2005
- CXC Chemokine Ligand 10 Controls Viral Infection in the Central Nervous System: Evidence for a Role in Innate Immune Response through Recruitment and Activation of Natural Killer CellsJournal of Virology, 2004
- Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparationsJournal of Comparative Neurology, 1999
- Early Murine Cytomegalovirus (MCMV) Infection Induces Liver Natural Killer (NK) Cell Inflammation and Protection Through Macrophage Inflammatory Protein 1α (MIP-1α)–dependent PathwaysJournal of Experimental Medicine, 1998